Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive carvedilol + atorvastatin with targeted-immunotherapy in cirrhotic advanced hepatocellular carcinoma
ChiCTR2500108002Phase 2Not yet recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carvedilol and atorvastatin in hepatocellular carcinoma (HCC) and Cirrhosis, sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: objective response rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
carvedilolatorvastatin
03
Conditions
hepatocellular carcinoma (HCC)Cirrhosis
Beyond the preview
Go deeper on ChiCTR2500108002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108002.